A shocking new study exposes deadly risks hidden in the abortion pill pushed by Big Pharma and pro-abortion activists. While the FDA turns a blind eye, women across America face life-threatening complications from mifepristone – with 1 in 10 suffering severe harm within weeks of taking the drug.
Lawmakers are demanding answers after research revealed abortion pill complications occur than the FDA’s watered-down reports suggest. Bleeding so heavy it requires emergency surgery. Rampant infections. Even deaths swept under the rug by profit-driven medical elites.
The FDA’s own commissioner admitted he hasn’t reviewed this damning new data – proof of a broken system putting radical ideology over women’s safety. While liberals cheer abortion-on-demand, real women pay the price with their health, fertility, and lives.
This isn’t “healthcare” – it’s chemical warfare on the unborn and their mothers. The abortion industry gets rich while leaving vulnerable women to suffer alone. Stories of hemorrhaging alone in bathrooms and ICU admissions are buried by pro-abortion media.
Mifepristone now accounts for most U.S. abortions, creating a public health crisis the Biden administration ignores. Medical experts confirm risks like toxic shock, uterine rupture, and sepsis – all dismissed as “rare” by abortion pushers.
Conservative leaders are fighting to protect women from this dangerous drug. They’re exposing how abortion providers downplay risks while pocketing cash from vulnerable patients. Every tragic complication reveals the lie of “safe and easy” abortion.
The FDA failed miserably to protect American women. It’s time to hold them accountable. Pro-life champions in Congress won’t rest until this lethal drug faces proper scrutiny – and until every woman knows the truth about Big Abortion’s deadly secrets.
Life is winning. As more Americans see the horrors of abortion pills, support grows for banning these dangerous drugs. The pro-life movement stands ready to help women choose life – and survive the abortion industry’s betrayal.
